Drug Target Review: Leading Research & Insights in Drug Discovery
Stay at the forefront of drug discovery and therapeutic development with Drug Target Review. Dive into the latest research, industry analysis and technological advancements. Connect with world-renowned scientists and explore peer-reviewed articles, webinars, and more.
Immuno-oncology innovations redefining cancer treatment in 2024
Jan 23, 2024 · Dr Espen Basmo Ellingsen. University of Oslo . Dr Ellingsen is a Medical Doctor and holds a PhD in cancer immunology from the University of Oslo. Background in translational research from the Institute for Cancer Research at Oslo University Hospital, focusing on therapeutic cancer vaccination, induced immune responses, and their impact on the tumor microenvironment.
unprecedented-fragment-based-screening-using-spectral-shift-for …
Oct 17, 2024 · Fragment-based drug design presents a unique opportunity to identify novel binding sites for membrane proteins. We leveraged fragment screening using the most recent biophysical technology, Spectral Shift, to discover antagonist hit fragments on the human adenosine A2A receptor.
How AI will reshape pharma in 2025 - drugtargetreview.com
Dec 20, 2024 · Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Concerns surrounding data security, the complexity of AI systems, and the rigorous regulatory frameworks in this field have caused the pharmaceutical industry to approach these technologies with caution.
Collaboration to advance automated insulin technology for diabetes
Jan 16, 2025 · The University of Virginia Center for Diabetes Technology and Tandem Diabetes Care have entered into a multi-year collaboration agreement to advance research and development in fully automated insulin delivery systems. This partnership will leverage the UVA Center’s groundbreaking work in improving diabetes care through technology-based interventions, along with Tandem’s expertise in ...
Tessera Therapeutics: addressing Alpha-1 Antitrypsin Deficiency
Jun 18, 2024 · Mike Holmes, PhD, Chief Scientific Officer at Tessera Therapeutics. Michael joined Tessera in December 2021 as Chief Scientific Officer. Dr Holmes has over 20 years of experience working on the development and clinical translation of different genome editing- and gene therapy-based strategies for the treatment of inherited and acquired diseases.
Eurofins launches new GMP certification for supplements
Jan 20, 2025 · Eurofins Healthcare Assurance has launched an innovative Good Manufacturing Practice (GMP) certification programme for dietary and food supplements. The initiative aims to improve compliance, safety, and quality across global supply chains. It is designed to help manufacturers, brands, agents, and retailers navigate the complex US regulatory landscape in the rapidly growing health and wellness ...
Drug candidates with blockbuster potential for CNS diseases
Sep 19, 2024 · Based on the positive efficacy and safety data generated in Phase I and II, the plan is to initiate a Phase III programme for mesdopetam. Following successful interactions at the End-of-Phase 2 meeting for mesdopetam with the US Food and Drug Administration (FDA) earlier this year we now look forward to the interactions with European drug regulatory authorities in the autumn for the start of a ...
New insights into the role of viral capsids in gene therapy safety
Dec 5, 2024 · Challenges of viral capsids in gene therapy efficiency . A widely used production method of rAAV vectors requires co-transfection of host cell lines with three plasmids, including one carrying the transgene of interest, one carrying the capsid and replication sequences, and a helper virus to circumvent the inability of rAAV to self …
Improving treatment responses to solid tumours with trispecific TCEs
May 23, 2024 · In comparison to comparator bispecific TCEs, what were the results of the TriTCE Co-Stim in humanised models of gastric cancer? The lead CLDN18.2 TriTCE Co-Stim mediated superior antitumour activity compared to the CLDN18.2 X CD3 bispecific from Amgen (AMG910) in an established gastric cancer model humanised with naïve human effector cells (peripheral blood mononuclear cells, PBMC).